



**APhA House of Delegates New Business Review Committee Report**  
Phoenix, Arizona

**New Business Review Committee**

Matthew Lacroix, Chair  
Ally Dering-Anderson  
Sarah Derr  
Shane Garrettson  
Mary Gurney  
Brian Hose  
Matthew Kirchoff  
John Pieper  
Traci Poole

The APhA House of Delegates New Business Review Committee (NBRC) presents the following report:

**NBI #1 – Development of veterinary pharmacy curricula in schools and colleges of pharmacy and pharmacy technology**

The APhA New Business Review Committee recommends adoption of New Business Item #1 Whole Numbered Statement #1 as amended.

1. APhA encourages schools and colleges of pharmacy and pharmacy technology to develop curriculums curricular opportunities for student pharmacists that educate pharmacists, student pharmacists, and pharmacy technicians to attain competencies in the principles of veterinary pharmacotherapy.

The committee recommends amendment of the proposed policy statement, noting that the development of “curricula” in principles of veterinary pharmacology may be more prescriptive and restrictive than intended. “Curricular opportunities” reflect the overall intent and principles for this policy.

The APhA New Business Review Committee recommends adoption of New Business Item #1 Whole Numbered Statement #2 as amended.

2. APhA encourages training of pharmacists and pharmacy technicians in the principles of veterinary pharmacotherapy.

The committee recommends addition of a second statement, to capture experiential education and training for pharmacy personnel in the principles of veterinary pharmacy.

## **NBI #2 – Uncompensated Care Mandates in Pharmacy**

The APhA New Business Review Committee recommends adoption of New Business Item #2 Whole Numbered Statement #1 as amended.

1. APhA expects calls for appropriate payment that all government, manufacturer, and payor policies for the provision of patient care, medical products and supplies, and related administrative services, appropriately recognize the role of pharmacists and pharmacies, and have adequate funding and accompanying mechanisms for reimbursement for all mandated pharmacist and pharmacy-provided services.

The committee recommends amendment of the proposed policy statement to maintain brevity, while also capturing the original intent to target payment for mandated pharmacist services. The committee also notes that “calls on” may be a stronger verb for this subject and intended audience.

The APhA New Business Review Committee recommends adoption of New Business Item #2 Whole Numbered Statement #2 as amended.

2. APhA calls for ~~expects that all government entities, manufacturers, and~~ payors ~~incorporate to be~~ transparent and perform comprehensive cost analyses ~~associated with the implementation of new programs in establishing reimbursements for requiring~~ pharmacist-provided patient care services, ~~medical products and supplies, and related administrative services.~~

The committee recommends amendment in the interest of brevity, while still capturing the original intent of advocating for cost analyses to determine appropriate payment for pharmacist services.

## **NBI #3 – Access to Reproductive Health Care Services**

The APhA New Business Review Committee recommends **adoption** of New Business Item #3 Whole Numbered Statement #1 as **amended**.

1. APhA supports equitable patient access to evidence-based comprehensive reproductive health care, including, but not limited to, the management of pregnancy loss, ectopic pregnancy, infertility, pregnancy termination, ~~sterilization, and~~ contraception, **and permanent contraception.**

The committee recommends “permanent contraception”, to utilize most current reproductive health care terminology. The feedback to incorporate such language was raised by delegates during webinars.

The APhA New Business Review Committee recommends **adoption** of New Business Item #3 Whole Numbered Statement #2 as **written**.

2. APhA recognizes patient autonomy in choosing reproductive health care services and the essential role of all health care professionals in facilitating access and advancing informed decision making.

The APhA New Business Review Committee recommends **adoption** of New Business Item #3 Whole Numbered Statement #3 as **written**.

3. APhA supports evidence-based legislation that ensures patient access to comprehensive reproductive health care services.

The APhA New Business Review Committee recommends **adoption** of the following as New Business Item #3 Whole Numbered Statement #4 as **written**.

4. **APhA opposes legal actions against pharmacies, pharmacists, and pharmacy personnel that provide patient access to, or information regarding, reproductive health care services that are within pharmacist scope of practice.**

The committee recommends integrating the statement originally presented via New Business Item #4 Statement #1, as an additional statement #4 to New Business Item #3, per delegate feedback during the Open Forums on APhA2023 New Business Items. This recommendation comes in consultation with the original New Business Item authors, to simplify the presentation of these policy statements relating to similar content. Additionally, based on feedback from open forums, the committee recommends the addition of “or information regarding”, to capture the full of scope of reproductive health care services which are within pharmacists’ scope of practice.

## **NBI #4 – Pharmacist Protection Related to Reproductive Health Care Services**

The APhA New Business Review Committee recommends **rejection** of New Business Item #4 Whole Numbered Statement #1 as **written**.

- ~~1. APhA opposes legal actions against pharmacies, pharmacists, and pharmacy personnel that provide patient access to reproductive health care services that are within pharmacist scope of practice.~~

The committee recommends integrating the statement originally presented via New Business Item #4 Statement #1, as an additional statement #4 to New Business Item #3, per delegate feedback during the Open Forums on APhA2023 New Business Items. Therefore, in order to execute this recommendation to integrate the statement to New Business Item #3, the committee must reject New Business Item #4 as a standalone motion. This recommendation comes in consultation with the original New Business Item authors, to simplify the presentation of these policy statements relating to similar content.

## **NBI #5 – Employer Responsibilities Related to Reproductive Health Care Access**

The APhA New Business Review Committee recommends **adoption** of New Business Item #5 Whole Numbered Statement #1 as **written**.

1. APhA advocates for employers to provide coverage and access to comprehensive reproductive health care services.

The APhA New Business Review Committee recommends **adoption** of New Business Item #5 Whole Numbered Statement #2 as **written**.

2. APhA demands that pharmacists and pharmacy personnel receive accommodations before, during and after pregnancy, including but not limited to sufficient time and space for breaks, opportunities to sit while working, and access to food and water between breaks.

## **NBI #6 – Pharmacist Representation on Medical Staff**

The APhA New Business Review Committee recommends **adoption** of New Business Item #6 Whole Numbered Statement #1 as **amended**.

1. APhA advocates for pharmacists to be included as members of ~~the~~ medical staffs and ~~to~~ be eligible to vote on the bylaws, standards, rules, regulations, and policies that govern ~~the those institutions'~~ medical staffs.

The committee recommends amendment, with the intent to maintain broad language that captures medical staff across all practice settings.

The APhA New Business Review Committee recommends **adoption** of New Business Item #6 Whole Numbered Statement #2 as **amended**.

2. APhA supports ~~that~~ pharmacists, as part of the medical staff, have parity in their opportunity to be credentialed and privileged as independent medical providers.

The committee recommends amendment to remove “that”, from a grammatic perspective.

## **NBI #7 – Greenhouse Gases**

The APhA New Business Review Committee recommends **adoption** of New Business Item #7 Whole Numbered Statement #1 as **amended**.

1. APhA urges ~~stakeholders within the pharmaceutical supply chain to reduce their greenhouse gas emissions~~ implementation of strategies throughout the pharmaceutical product lifecycle (e.g., research, development, manufacturing, marketing, distribution, dispensing, use, and disposal) to achieve net zero emissions by 2050.

The committee recommends amendment, to broaden the scope of gas emissions beyond greenhouse gases, while also providing a target reduction for stakeholders to strive for. This comes as a result of delegate questions and feedback during the webinar sessions.

## **NBI #8 – Access to Essential Medicines**

The APhA New Business Review Committee recommends **adoption** of New Business Item #8 Whole Numbered Statement #1 as **amended**.

1. APhA ~~encourages~~ **advocates regulation, policies and legislation that recognize** access to quality and affordable essential medicines as a fundamental human right.

The committee recommends an amendment to the proposed policy statement, to strengthen the intended purpose of the proposed policy, and clarify the relevant stakeholders.

## **NBI #9 – Antidiscrimination**

The APhA New Business Review Committee recommends **adoption** of New Business Item #9 Whole Numbered Statement #1 as **amended**.

1. APhA ~~affirms its support of~~ **advocates for** patients ~~obtaining to obtain~~ medications from pharmacies, free from discrimination.

The committee recommends condensing the two originally proposed policy statements into one, so as not to be repetitive nor dilute the overall intent. Based on feedback from open forums, the committee also recommends “advocates for”, as a stronger verb choice.

The APhA New Business Review Committee recommends **rejection** of New Business Item #9 Whole Numbered Statement #2 as **written**.

2. ~~APhA opposes discrimination on the basis of disability, pregnancy or related conditions.~~

The committee recommends condensing the two originally proposed policy statements into one, so as not to dilute the overall intent; thus, a second statement is not needed after the first statement.

## **NBI #10 – Pharmacy Shortage Areas**

The APhA New Business Review Committee recommends **adoption** of New Business Item #10 Whole Numbered Statement #1 as **written**.

1. APhA recognizes geographic proximity and transportation to pharmacies as key determinants in equitable access to medications, vaccines, and patient care services.

**The APhA New Business Review Committee recommends adoption of New Business Item #10 Whole Numbered Statement #2 as written.**

2. APhA calls for laws, regulations, and policies that reduce pharmacy shortage areas and ensure equitable access to essential services.

**The APhA New Business Review Committee recommends adoption of New Business Item #10 Whole Numbered Statement #3 as written.**

3. APhA supports the development of financial incentives to establish physical pharmacy locations in pharmacy shortage areas and to prevent the closure of pharmacies in underserved areas.

## **NBI #11 – Legalization or Decriminalization of Illicit Drugs**

**The APhA New Business Review Committee recommends adoption of New Business Item #11 Statement #2 as written within the *2016, 1990 Legalization or Decriminalization of Illicit Drugs Policy*.**

2. APhA supports decriminalization of the possession or use of illicit drug substances or paraphernalia.

**The APhA New Business Review Committee recommends adoption of New Business Item #11 Statement #3 as written within the *2016, 1990 Legalization or Decriminalization of Illicit Drugs Policy*.**

3. APhA supports voluntary pathways for the treatment and rehabilitation of individuals who are charged with the possession or use of illicit drug substances and who have substance use or other related medical disorders.

**APhA New Business Review Committee recommends adoption of New Business Item #11 Statement #4 as written within the *2016, 1990 Legalization or Decriminalization of Illicit Drugs Policy*.**

- ~~4. APhA supports the use of drug courts or other evidence-based mechanisms when appropriate as determined by the courts to provide alternate pathways within the legal criminal justice system for the treatment and rehabilitation of individuals who are charged with drug-related offenses and who have substance use or other related medical disorders.~~

**APhA New Business Review Committee recommends adoption of New Business Item #11 Statement #5 as amended within the 2016, 1990 Legalization or Decriminalization of Illicit Drugs Policy.**

- ~~5. APhA supports criminal penalties for persons convicted of drug-related crimes, including but not limited to drug trafficking, drug manufacturing, and or drug diversion, whenever alternate pathways are inappropriate as determined by the courts.~~

The author(s) of New Business Item #11 proposed amendments to the existing 2016, 1990 Legalization of Decriminalization of Illicit Drugs APhA policy, with the rationale to reflect modern language and practices in the fields of drug criminalization and illicit drugs. These recommendations include retainment of the original statement #1, addition of new statements #2 and #3 as shown above, removal of statement #4 as shown above, and amendment to language already included in existing policy shown above as Statement #5. The committee recommends adoption of the New Business Item authors' recommendations for Statements #2, #3, and #4 as shown above (indicated in black text). However rather than accepting the proposed edits to Statement #5 by the NBI authors, the committee recommends removing this statement altogether (as indicated in red text).

## **NBI #12 – Transgender and Nonbinary Health Care**

**The APhA New Business Review Committee recommends adoption of New Business Item #12 Whole Numbered Statement #1 as amended.**

1. APhA supports the enactment by state and federal legislatures to establish laws and policies to end discriminatory practices that limit access to care for transgender and nonbinary ~~(TNB)~~ people.

The committee recommends amendment of all three statements of New Business Item #12 to remove acronyms so that each individual policy statement may stand alone.

**The APhA New Business Review Committee recommends adoption of New Business Item #12 Whole Numbered Statement #2 as amended.**

2. APhA advocates for intentional ~~recruitment inclusion~~ of ~~the transgender and nonbinary TNB community individuals~~ in clinical research.

The committee recommends amendment of all three statements of New Business Item #12 to remove acronyms so that each individual policy statement may stand alone. The committee recommends "recruitment" over inclusion, to more accurately convey the intent of seeking transgender and nonbinary individual representation in studies.



The APhA New Business Review Committee recommends adoption of New Business Item #12 Whole Numbered Statement #3 as amended.

3. APhA encourages equity in care for transgender and nonbinary ~~TNB~~ individuals through:
  - a) ~~Offering accredited~~ Continuing education on the pharmacist's role in transgender care, gender-affirming therapy, and health disparities in transgender and nonbinary ~~TNB~~ patients.
  - b) Systematic integration and utilization of affirmed name and pronouns, gender identity, and anatomical inventory.
  - c) Availability and implementation of education and resources related to gender-diverse care for all persons employed in health care settings.

<p>The committee recommends amendment of all three statements of New Business Item #12 to remove acronyms so that each individual policy statement may stand alone.</p>
---